Vaxcyte (PCVX) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental metrics average 5.2/10, indicating a mixed picture. Strengths include strong cash‑to‑market (Cash‑MV), high inventory turnover, solid fixed‑asset utilization and robust YoY revenue growth. Weak points are low Revenue‑MV, modest PB‑ROE, thin gross margin and elevated income‑tax ratio.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.48%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.22%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.55%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.17%

1M Return-0.63%

PB-ROE

Value0.91

Score0/3

Weight8.33%

1M Return3.23%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.95%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.13%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.57%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight35.13%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight14.70%

1M Return5.94%

Is PCVX undervalued or overvalued?

PCVX scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -25.59% ROE, 0.00% net margin, -11.05 P/E ratio, 3.15 P/B ratio, and -48.16% earnings growth, these metrics solidify its Netural investment rating.